# SES AI Corp: Form 10-Q for the period ended Sep 30, 2023

- Company: [SES AI Corp](/companies/ses.md) (CIK 1819142)
- Form: 10-Q
- Filed: 2023-11-07
- Accepted by EDGAR: Nov 7, 2023, 16:32 ET
- Period: 2023-09-30
- Accession: 0001819142-23-000087
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1819142/000181914223000087/ses-20230930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1819142/000181914223000087/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2023-07-01 to 2023-09-30 | $8.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2023-01-01 to 2023-09-30 | $23.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-07-01 to 2023-09-30 | −$19.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-01-01 to 2023-09-30 | −$60.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2023-07-01 to 2023-09-30 | $208.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-01-01 to 2023-09-30 | $678.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-07-01 to 2023-09-30 | −$13.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-01-01 to 2023-09-30 | −$42.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-07-01 to 2023-09-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2023-01-01 to 2023-09-30 | −$0.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-07-01 to 2023-09-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2023-01-01 to 2023-09-30 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-07-01 to 2023-09-30 | 315,627,263 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-01-01 to 2023-09-30 | 314,550,810 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-01-01 to 2023-09-30 | −$43.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2023-01-01 to 2023-09-30 | $12.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-09-30 | $49.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-09-30 | $352.1m | us-gaap:AssetsCurrent |
| Total assets | at 2023-09-30 | $403.3m | us-gaap:Assets |
| Current liabilities | at 2023-09-30 | $15.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-09-30 | $39.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-09-30 | $363.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 30,709 characters.

*The following discussion and analysis provides information which our management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. The following discussion and analysis should be read in conjunction with the accompanying unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September 30, 2023 and the related notes included in this Quarterly Report on Form 10-Q and our audited consolidated financial statements as of and for the year ended December 31, 2022 and the related notes contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 16, 2023 (the “2022 Annual Report”). This Quarterly Report on Form 10-Q includes forward-looking statements. These forward-looking statements within the meaning of the federal securities law are based on our current expectations and beliefs concerning future developments and their potential effects on us. These forward-looking statements are not statements of historical fact and may include statements regarding possible or assumed future results of operations. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Factors that might cause or contribute to such forward-looking statements include, but are not limited to, those set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q and in Item 1A. Risk Factors in the 2022 Annual Report. Unless the context otherwise requires, references in this section to “the Company,” “we,” “us” and “our” refer to the business and operations of SES Holdings Pte. Ltd. (“Old SES”) and its consolidated subsidiaries prior to the Business Combination and to SES AI Corporation and its consolidated subsidiaries following the Closing. References in this section to our future plans that indicate the timing of when we expect such plans to be completed by a certain year mean at any point during that year.*

### Overview

We are a pre-commercialization stage company engaged in the development and production of high-performance, Lithium-Metal (“Li-Metal”) rechargeable battery technologies for electric vehicles (“EVs”), Urban Air Mobility (“UAM”) and other applications. Our differentiated battery technology has been designed to combine the high energy density of Li-Metal with the large-scale manufacturability of conventional Lithium-ion (“Li-ion”) batteries and will help to promote the transition from the global dependence on fossil fuel-based automotive vehicles to clean and efficient EVs.

Our mission is to facilitate the widespread adoption of sustainable electric transportation, both on land and in air, by creating best-in-class, high energy density Li-Metal batteries centered around long-range performance and safety. To assist in achieving this mission, we have partnered with leading global original equipment manufacturers (“OEMs”), General Motors (“GM”), Hyundai Motor Company (“Hyundai”), and Honda Motor Company, Ltd. (“Honda”), among other strategic partners, under joint development agreements (“JDAs”) to jointly develop and produce our Li-Metal battery cells and technology. We are currently working to transition from the development and production of A-Sample batteries to B-Sample batteries with specifications required by OEMs for their EVs. A-Sample batteries are functional prototypes developed for OEMs based on their technical specifications. These are in contrast with B-Sample batteries, which are A-sample batteries manufactured under much higher throughput and tested in actual vehicles, and C-Sample batteries, which would be fully functional, mature samples for mass production and tested for full drivability.

We are also conducting research and development activities to further improve the performance, quality and cost of our battery technology by focusing on the following key areas, all of which we expect to help us achieve our commercialization goal, at our facilities in Woburn, Massachusetts in the United States, Shanghai, China, and Chungju, South Korea. These activities include:

- *Scale-up*: Our design is further being customized with and validated by several OEMs. Based on our collaborations with OEMs, we believe that a roughly 100 Ah cell-size manufactured at GWh scale (five to seven cells-per-minute) is needed to achieve commercialization in EVs at a large, global scale. We are developing processes and equipment to scale up the manufacturing of our current cell design from three to nine Ah capacity to 50 Ah and 100 Ah.
- *Module and Pack Design*: Li-Metal cells must be integrated into modules and packs as part of their integration into vehicles. Our active development efforts are focused on the integration of our Li-Metal cells in modules to enable our Li-Metal cells to perform as intended once they are integrated into modules and vehicles.
- *Advanced Artificial Intelligence (“AI”) Software and Battery Management Systems (“BMS”)*: Software is critical to ongoing monitoring of battery health and safety. We continue to develop advanced AI algorithms to diagnose battery cell-related health issues, develop advanced control algorithms and charging methods to enhance cycle life and safety, and port such software on to a BMS that could be integrated into a battery pack.
- *Advanced Materials and Coatings*: We continue to research and develop advanced electrolyte and anodes to further improve cycle life and safety. In addition, we continue to develop novel methods of laminating or depositing lithium metal onto current collector that can be deployed at commercial GWh scale.
- *Cathode Materials and Design*: We develop our Li-Metal cells for a variety of different cathode materials, cathode design and cathode processing methods that can provide ultra-high energy density and/or significant cost-reduction.
- *Li-Metal Recycling*: Along with other battery components that are already being recycled today, Li-Metal foil will also need to be recycled in the future. We continue to explore methods of recycling that are productive and cost-effective.

We continue to make improvements to our three A-sample production lines, one in China and two in South Korea, which are producing and testing large 50 Ah and 100 Ah Li-Metal cells. We expect to launch our fourth production line in 2024, which will be dedicated to B-sample EV cells. In addition, we are also planning to build a fifth production line, which will be dedicated to B-sample battery cells for UAM applications. Furthermore, in July 2023, we entered into a new lease for a facility near our Woburn facility where we will be building an electrolyte foundry, which will focus on novel electrolyte molecule discovery and synthetic pathway development and which we expect to be ready by early 2024.

### Outlook

As the joint development of Li-Metal batteries with our OEM partners continues to progress, we expect this will allow us to transition from A-sample to B-sample battery development by the last quarter of 2023. Further, this will lead to an increase in our headcount and footprint of our research and pre-production pilot facilities as we expand our existing facilities and entering into new facilities.

After B-Sample, we plan to transition to C-Sample in 2024, which we then expect to enable us to commence commercial production of our technology in 2025. We expect this transition to commercial production to lead to future research facilities and, eventually, commercial production manufacturing facilities in the United States, which will significantly increase our materials consumption and the rate of cash utilization over time.

Finally, we expect to explore opportunities for partial vertical integration, both upstream and downstream, to ensure scalability of our battery cells and battery technology. Upstream, we intend to explore integrating vendors of key materials of our cells and providers of key equipment and engineering capabilities, such as cell assembly, anode processing, chemical processing and safety testing. Downstream, we plan to explore integrating providers of key engineering capabilities, such as battery state-of-health monitoring software, charging optimization software, battery module development and recycling.

### Results of Operations

#### Factors Affecting Operating Results

As a pre-commercialization company, we have not generated any revenue from sales to customers to date through our one operating segment. We have spent $11.4 million and $11.7 million on gross research and development activities during the three months ended September 30, 2023 and 2022, respectively, and $37.7 million and $28.8 million on gross research and development activities during the nine months ended September 30, 2023 and 2022, respectively, which is prior to credits received by our OEM partners under the JDAs. As a result, we have incurred losses from operations of $19.4 million and of $21.7 million for the three months ended September 30, 2023 and 2022, and losses from operations of $60.2 million and $60.0 million for the nine months ended September 30, 2023 and 2022, respectively. Our historical results may not be indicative of our future results for reasons that may be difficult to anticipate and our ability to generate revenue in the future that is sufficient enough to achieve profitability will depend largely on the successful development of our products. Accordingly, the drivers of our future financial results, as well as the components of such results, may not be comparable to our historical results of operations.

The following table sets forth our historical operating results for the periods indicated:

*(in thousands)*

| ​ ​ | ​ ​ Three Months Ended September 30, 2023 | ​ ​ | ​ ​ 2022 | ​ ​ ​ | ​ ​ $​% Change | ​ ​ | ​ ​ Change |
| --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Research and development | $8,472 | ​ | $8,421 | ​ | $51 | ​ | 0.6% |
| General and administrative | ​ 10,885 | ​ | ​ 13,308 | ​ | ​ (2,423) | ​ | (18.2)% |
| **Total operating expenses** | $19,357 | ​ | $21,729 | ​ | $(2,372) | ​ | (10.9)% |

*(in thousands)*

| ​ ​ | ​ ​ Nine Months Ended September 30, 2023 | ​ ​ | ​ ​ 2022 | ​ ​ ​ | ​ ​ $​% Change | ​ ​ | ​ ​ Change |
| --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Research and development | $23,308 | ​ | $19,680 | ​ | $3,628 | ​ | 18.4% |
| General and administrative | ​ 36,932 | ​ | ​ 40,305 | ​ | ​ (3,373) | ​ | (8.4)% |
| **Total operating expenses** | $60,240 | ​ | $59,985 | ​ | $255 | ​ | 0.4% |

#### Research and Development

Research and development expenses consist primarily of costs incurred for personnel-related costs for scientists, engineers and technicians, including salaries, bonus and stock-based compensation expense, expenses for materials and supplies used in product research and development, process engineering efforts and testing, as well as payments to consultants, depreciation, and allocated facilities and information technology costs. Additionally, payments received from the JDA agreements are treated as credits to research and development expenses.

Research and development expenses for the three months ended September 30, 2023 increased $0.1 million, or 0.6%, to $8.5 million, compared with $8.4 million for the three months ended September 30, 2022. This increase was primarily driven from a $2.6 million increase in personnel costs mainly attributable to our growth in headcount to support our operations, $1.8 million increase in facility related costs such as rent, utilities and depreciation expenses, a $0.7 million increase in professional consulting services, and a $0.9 million decrease in credits to research and development expenses from decreased billings to our JDA partners. These increases were partially offset by a $3.8 million decrease in stock-based compensation mainly attributable to forfeited awards, a $1.2 million decrease in software development costs due to change in project specifications and timelines, and a $1.0 million decrease in lab equipment and material supplies to support JDA activity in our research and pre-production facilities.

Research and development expenses for the nine months ended September 30, 2023 increased $3.6 million, or 18.4%, to $23.3 million compared with $19.7 million for the nine months ended September 30, 2022. The increase primarily resulted from a $6.2 million increase in personnel costs mainly attributable to our growth in headcount to support our operations, a $4.6 million increase in facility related costs such as increased rent, utilities and depreciation expenses, $2.2 million increase in lab equipment and material supplies to support JDA activity in our research and pre-production facilities, and a $1.0 million increase in professional consulting services. These increases were partially offset by a $6.6 million increase in credits to research and development expenses from billings to our JDA partners, a $2.1 million decrease in stock-based compensation mainly attributable to forfeited awards and the earn-out shares fully expensed due to completion of derived service period during the current quarter, and a $1.9 million decrease in computer and software development costs due to a change in project specifications and timelines.

#### General and Administrative

General and administrative expenses consist primarily of costs incurred for personnel-related expenses for our finance, legal and human resource functions, including salaries, bonus and stock-based compensation expense, expenses for director and officer insurance, professional service fees, audit and compliance expenses, legal fees, patent related costs, accounting and other advisory services, as well as allocated facilities and information technology costs including depreciation. Upon commencement of commercial operations, we also expect to incur customer and sales support and advertising costs.

General and administrative expenses for the three months ended September 30, 2023 decreased $2.4 million, or 18.2%, to $10.9 million, compared with $13.3 million for the three months ended September 30, 2022. This decrease was primarily driven by a $1.3 million decrease in insurance expense due to lower premiums incurred to cover potential liabilities under our indemnification obligations to our directors and certain officers of the Company, a $0.9 million decrease in marketing and public relations expenses due to a decrease in promotional events, and a decrease of $0.9 million of stock-based compensation expense that primarily related to the earn-out shares fully expensed due to completion of derived service period during the current quarter. These decreases were partially offset by a $0.4 million increase in personnel costs mainly attributable to our growth in headcount to support our operations and compliance as a public company and a $0.1 million decrease in professional consulting services.

General and administrative expenses for the nine months ended September 30, 2023 decreased $3.4 million, or 8.4%, to $36.9 million, compared with $40.3 million for the nine months ended September 30, 2022. This decrease was primarily driven by a decrease of $4.7 million of transaction costs incurred in the prior year period as a result of the Business Combination completed in February 2022 with no comparable costs in the current period, a $2.5 million decrease in insurance expense due to lower premiums incurred to cover potential liabilities under our indemnification obligations to our directors and certain officers of the Company compared to the prior year period, and a $1.7 million decrease in marketing and public relations expenses due to a decrease in promotional events compared to the prior year period. These decreases were partially offset by an increase of $2.4 million of stock-based compensation expense that primarily related to the effect of restricted and performance stock units granted subsequent to the corresponding prior year period, a $1.8 million increase in personnel costs mainly attributable to our growth in headcount to support our operations and compliance as a public company, a $0.6 million increase in professional fees related primarily to increased recruiting and consulting services, a $0.4 million increase in accounting and audit related expenses, and a $0.3 million increase in legal fees to support our operations as a public company.

### Non-Operating Items

#### Interest Income, Net

Interest income primarily consists of interest earned on our cash and cash equivalents and marketable debt securities, which are primarily invested in money market funds and U.S. treasury securities, and accretion income from the U.S. treasury securities.

During the three and nine months ended September 30, 2023, we had interest income of $4.2 million and $12.5 million, respectively, compared with $2.0 million and $2.5 million for the three and nine months ended September 30, 2022, respectively. The $2.2 million and $10.0 million increases from the three and nine months ended September 30, 2022 to the three and nine months ended September 30, 2023, respectively, were primarily due to a change in our investment strategy of investing in higher yielding U.S. treasury securities during the fourth quarter of 2022. Our investment strategy for the first three quarters of 2022 was investing in money market funds.

#### Change of Fair Value of Earn-Out Liability, Net

During the three and nine months ended September 30, 2023, we incurred a gain of $1.9 million and $5.4 million, respectively, associated with the change in fair value of the Sponsor Earn-Out Liability compared with a loss of $4.9 million and a gain of $16.4 million, respectively, for the three and nine months ended September 30, 2022. With the fair value of the Sponsor Earn-Out Liability tied to the Company’s stock price, continued volatility in the stock price could result in further gains or losses. Refer to “Note 8 – Sponsor Earn-Out Liability” to the condensed consolidated financial statements for additional information.

#### Other (Expense) Income, Net

During the three months ended September 30, 2023, we had other expense of less than $0.1 million, compared with other income of $0.4 million for the three months ended September 30, 2022. This $0.4 million decrease in other income was primarily as a result of lower realized foreign currency gains on Chinese renminbi (CNY) in the current year period.

During the nine months ended September 30, 2023, we had other income of $0.4 million, compared with other expense of $0.9 million for the nine months ended September 30, 2022. This $1.3 million increase in other income was primarily the result of the accounting for certain postemployment benefits in the prior year period.

#### Provision for Income Taxes

The provision for income taxes for the three and nine months ended September 30, 2023 increased to $0.2 million and $0.7 million, compared to $0.1 million and $0.3 million for the three and nine months ended September 30, 2022, respectively, primarily due to local tax in the foreign jurisdictions in which the Company operates.

### Liquidity and Capital Resources

As of September 30, 2023, we had total cash and cash equivalents of $49.9 million and investments in marketable debt and equity securities of $292.2 million. As a pre-commercialization stage research and development company, the net operating losses we have incurred since inception are consistent with our strategy and within our budgeted expenditures.

We expect to sustain substantial operating expenses, due to the capital-intensive nature of our research and development activities, without generating sufficient revenues to cover expenditures for a number of years. To date, we have funded our operations through a combination of our cash on hand, which primarily originated from proceeds from the Business Combination and PIPE Financing and from funding received through the sales of our redeemable convertible preferred stock, proceeds from the JDAs with our OEM partners and investment income. These funds are expected to finance our principal sources of liquidity and ongoing costs, such as research and development relating to our Li-Metal batteries and the construction of additional manufacturing facilities. In the future, if we are not able to fund our operations from cash flows generated from anticipated product sales, we expect that we will need to raise additional funds through a variety of possible methods, including, but not limited to, entry into joint ventures or other strategic arrangements, issuance of equity, equity-related or debt securities or through obtaining credit from financial institutions, as well as anticipated future revenue from product sales.

We believe that our cash on hand and marketable securities will be sufficient to meet our working capital and capital expenditure requirements for a period of at least 12 months from the date of this Quarterly Report on Form 10-Q, and also sufficient to fund us to commercialization. However, additional funding may be required for a variety of reasons, including opportunities to build an integrated supply chain in the United States and delays in expected development of our Li-Metal battery cells. Our ability to successfully develop our products, commence commercial operations and expand our business will depend on many factors, including our working capital needs, the availability of equity and/or debt financing and, over time, our ability to generate positive cash flows from operations.

### Summary of Cash Flows

The following table provides a summary of our cash flow data for the periods indicated:

*(in thousands)*

| ​ ​ Cash (used in) provided by: | ​ ​ Nine Months Ended September 30, 2023 ​ ​ | ​ ​ ​ | ​ ​ 2022 ​ ​ |
| --- | --- | --- | --- |
| Operating activities | $(43,894) | ​ | $(37,807) |
| Investing activities | ​ (12,332) | ​ | ​ (10,645) |
| Financing activities | ​ 157 | ​ | ​ 283,200 |
| Effect of exchange rate changes on cash | ​ (664) | ​ | ​ (639) |
| **Net (decrease) increase in cash, cash equivalents and restricted cash** | $(56,732) | ​ | $234,109 |

### Operating Activities

Our operating activities have primarily comprised research and development and general and administrative activities as discussed above. As we continue to ramp up hiring for research and development headcount to accelerate our engineering efforts, we expect our cash used in operating activities to increase significantly before we start to generate any material cash inflows from our operations.

Net cash used in operating activities of $43.9 million for the nine months ended September 30, 2023 was primarily attributable to net loss of $42.6 million, as adjusted for stock-based compensation expense of $16.2 million, accretion income from marketable securities of $8.6 million, a gain on change in fair value of Sponsor Earn-Out Liability of $5.4 million, depreciation and amortization of $3.9 million and a $6.8 million working capital outflow. The working capital outflow was primarily driven by a $3.8 million decrease in accrued expenses and other liabilities and a $3.3 million increase in prepaids and other assets, partially offset by a $0.6 million dollar increase in accounts payable. The increase in prepaids and other assets was primarily due to amounts due from JDA partners, the renewal of an insurance contract to cover potential liabilities under our indemnification obligations to our directors and certain officers and prepaid costs related to software development. The decrease in accrued expenses and other liabilities was primarily due to the release of deferred liabilities related to JDAs. The increase in accounts payable was primarily due to the timing of payments.

Net cash used in operating activities of $37.8 million for the nine months ended September 30, 2022 was primarily attributable to net loss of $42.3 million as adjusted for a gain on change in fair value of Sponsor Earn-Out liability of $16.4 million, stock-based compensation expense of $15.9 million, and depreciation and amortization of $1.6 million, partially offset by a $3.8 million working capital cash inflow. The working capital cash inflow was driven by a $5.9 million decrease in receivable from a related party and a $2.0 million increase in accrued expenses and other liabilities, partially offset by a $3.4 million increase in prepaids and other assets and a $0.8 million decrease in accounts payable. The decrease in receivable from related party was driven by activity from the JDAs. The increase in accrued expenses and other liabilities was primarily due to certain postemployment benefits. The increase in prepaids and other assets was primarily due to insurance costs to cover potential liabilities under our indemnification obligations to our directors and certain officers and receivables from our other JDAs. The decrease in accounts payable was primarily driven by the timing of payments.

### Investing Activities

Net cash used in investing activities was $12.3 million for the nine months ended September 30, 2023, compared to net cash used in investing activities of $10.6 million for the nine months ended September 30, 2022.

*Purchases and Maturities of Investments –* Net purchases of investments in marketable debt and equity securities were $0.1 million for the nine months ended September 30, 2023, compared to no purchases of investments during the nine months ended September 30, 2022.

*Capital Spending –* Capital expenditures were $12.3 million and $10.6 million for the nine months ended September 30, 2023 and 2022, respectively, and primarily related to the timing of purchases of lab machinery and equipment, lab tools and instruments related to our build out of production lines and facilities. We expect capital expenditures for the rest of 2023 to increase compared with the corresponding period in 2022 as we continue to invest in the build out of our fourth and fifth production lines and research and development facilities.

### Financing Activities

Net cash provided by financing activities was $0.2 million for the nine months ended September 30, 2023 related to proceeds from option exercises.

Net cash provided by financing activities of $283.2 million for the nine months ended September 30, 2022 primarily related to proceeds received from the Business Combination and PIPE Financing, net of transaction costs.

### Contractual Obligations and Commitments

The following table summarizes our material contractual obligations for cash expenditures as of September 30, 2023, and the periods in which these obligations are due:

| ​ ​ | ​ ​ Short Term | ​ ​ | ​ ​ Long Term | ​ ​ | ​ ​ Total |
| --- | ---: | --- | ---: | --- | ---: |
| Purchase obligations(1) | $33,334 | ​ | $24,681 | ​ | $58,015 |
| Operating lease obligations(2) | **​** 2,754 | ​ | **​** 10,086 | ​ | **​** 12,840 |
| Total | $36,088 | ​ | $34,767 | ​ | $70,855 |

(1) Purchase obligations include commitments for the purchase of lab supplies and equipment as well as committed spend related to a JDA. These commitments are derived from purchase orders, supplier contracts and open orders based on projected demand information.

(2) Operating lease obligations represent the fixed lease payments for the noncancelable lease term, fixed lease payments for optional renewal periods where the Company is reasonably certain the renewal option will be exercised, and variable lease payments that depend on an underlying index or rate in effect at lease commencement.

### Off-Balance Sheet Arrangements

As of September 30, 2023, we had a letter of credit issued by a financial institution totaling $0.6 million. The letter of credit relates to deposits the Company is required to maintain for one of its operating lease agreements. We have restricted cash that serves as collateral for this outstanding letter of credit that is included in other assets on our condensed consolidated balance sheet. No amounts have been drawn under the letter of credit.

### Recent Accounting Pronouncements

See “Note 2 – Basis of Presentation” of our accompanying unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023 included in this Quarterly Report on Form 10-Q for more information about recent accounting pronouncements, the timing of their adoption, and their potential impact on our financial condition, results of operations and cash flows.

### Critical Accounting Estimates and Judgments

Our financial statements have been prepared in accordance with U.S. GAAP. In the preparation of these unaudited condensed consolidated financial statements, we are required to use judgment in making estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the unaudited condensed financial statements, as well as the reported expenses incurred during the reporting periods.

There have been no significant changes to our critical accounting policies or in the underlying accounting assumptions and estimates used in such policies from those disclosed in our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2022.

### Other Information

The Company’s website is www.ses.ai. Information contained on the Company’s website is not part of this report. Information that we furnish to or file with the SEC, including the Company’s annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to, or exhibits included in, these reports are made available for download, free of charge, through the Company’s website as soon as reasonably practicable. The Company’s SEC filings, including exhibits filed therewith, are also available directly on the SEC’s website at www.sec.gov.

The Company may use its website as a distribution channel of material company information. Financial and other important information regarding the Company is routinely posted on and accessible through the Company’s website at www.ses.ai. Accordingly, investors should monitor this channel, in addition to following the Company’s press releases, SEC filings and public conference calls and webcasts. The contents of our website are not, however, a part of this report.

## Market risk

As filed, 335 characters.

There have been no significant changes to the Company’s market risk during the three months ended September 30, 2023. Refer to “Part II. Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2022 for a discussion of the Company’s exposure to market risk.

## Controls and procedures

As filed, 5,657 characters.

### Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our chief executive officer (“CEO”) and chief financial officer (“CFO”), we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2023, as such term is defined in Rules 13a-15(e) and 15d-15(e) under Securities Exchange Act of 1934, as amended (the “Exchange Act”). Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of September 30, 2023, our disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting, as discussed in more detail below.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Notwithstanding the identified material weaknesses, management, with the participation of the principal executive officer and principal financial officer, believes the condensed consolidated financial information included in this Quarterly Report on Form 10-Q fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.

### Material Weaknesses

We previously identified material weaknesses, as disclosed in our 2022 Annual Report.

Certain components of the Company’s control environment were ineffective as the Company did not have a sufficient complement of resources with assigned responsibility and accountability for the design, operation and documentation of internal control over financial reporting. This created deficiencies in the Company’s risk assessment process that led to ineffective information and communication activities as the controls necessary to ensure the reliability of information used in financial reporting and communicate relevant information about roles and responsibilities for internal control over financial reporting were ineffective. As a result, process-level control activities were not designed, implemented or operated effectively in the substantial majority of our processes.

### Changes in Internal Control over Financial Reporting

Other than the actions taken as described in “Management’s Remediation Initiatives” below to improve the Company’s internal control over financial reporting, there have been no changes in our internal control over financial reporting during the most recent fiscal quarter that materially affected, or which are reasonably likely to materially affect, our internal control over financial reporting.

### Management’s Remediation Initiatives

We have taken the following steps towards remediation of the identified material weaknesses and to enhance our internal control over financial reporting:

- We have developed a detailed remediation plan, with appropriate executive sponsorship and with the assistance of a national accounting firm, to specifically address the material weaknesses.
- We have hired, and will continue to hire, additional certified public accountants (including those with public company experience) who have the appropriate level of expertise in the areas of accounting, financial reporting, and internal controls commensurate with the volume and complexity of our reporting requirements.
- We have taken steps to enhance the design of existing control activities and implement additional process-level control activities and ensure they are operating effectively.
- We have taken steps to design and implement additional information and communications controls to ensure use of and obtain relevant and quality information to allow operation of effective control activities, including internal and external communication.
- We are improving our capabilities to identify, research, and prepare supporting documentation for technical accounting issues.
- We have enhanced our risk assessment process, and will continue to make it a more comprehensive and continuous process, to identify and assess risks of material misstatements and ensure that the related internal controls are properly designed and in place to respond to those risks.
- We have taken steps to implement new IT applications which will automate some of the manual financial reporting processes.

We have expended, and will continue to expend, a substantial amount of effort and resources for the remediation and improvement of our internal control over financial reporting. We will continue to work on improvements to our internal controls during 2023 as we assess and evaluate the controls intended to remediate the material weaknesses. Until these weaknesses are remediated, we plan to continue to perform additional analyses and other procedures to ensure that our consolidated financial statements are prepared in accordance with GAAP.

## Risk factors

As filed, 689 characters.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors disclosed in “Part I, Item 1A” of our Annual Report on Form 10-K for the year ended December 31, 2022, and the other reports that we have filed with the SEC. Any of the risks discussed in such reports, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial condition or prospects. During the period covered by this Quarterly Report on Form 10-Q, there have been no material changes in our risk factors as previously disclosed.

Filed Nov 7, 2023.
Source: SEC EDGAR, the filing index for accession 0001819142-23-000087. Last ingested by Listed: Nov 13, 2026, 16:22 ET. No prices; not investment advice.
